RYTM

Rhythm Pharmaceuticals, Inc.

43.70 USD
-0.01 (-0.02%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Rhythm Pharmaceuticals, Inc. stock is down -2.63% since 30 days ago. The next earnings date is Apr 30, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 6 March’s closed higher than February. In the last 9 Unusual Options Trades, there were 3 CALLs, 6 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
09 Jan 18:49 16 Feb, 2024 40.00 CALL 50 200
10 Jan 14:30 19 Jan, 2024 30.00 CALL 41 362
12 Jan 15:53 19 Apr, 2024 50.00 CALL 1000 7
31 Jan 16:37 19 Jul, 2024 50.00 PUT 75 50
01 Feb 20:34 15 Mar, 2024 60.00 PUT 25 0
13 Feb 14:47 20 Dec, 2024 40.00 PUT 50 0
22 Feb 20:31 15 Mar, 2024 45.00 PUT 103 21
22 Feb 20:31 15 Mar, 2024 45.00 PUT 92 21
22 Feb 20:44 20 Dec, 2024 35.00 PUT 150 50

About Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency.